In November 2020, ESO-WSO provided scientific updates to Health Care Practitioners. During this conference, 4 abstracts on NeuroAiD’s safety and efficacy in post-stroke recovery are presented by international speakers.
- NeuroAiDTMII holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression
- WSD ebook
- Moleac Pte Ltd wins SBR National Business Award for Pharmaceuticals
- Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery
- ESOC 2020: Abstracts on NeuroAiD